The University of Southampton
University of Southampton Institutional Repository

Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program

Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program
Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program
Idiopathic pulmonary fibrosis is the most lethal form of diffuse lung fibrosis, killing approximately half of those affected within 2-3 years of diagnosis. Until recently, no therapies had been shown to have an impact on disease progression. The Clinical Studies Assessing Pirfenidone (Esbriet(®)) in IPF: Research of Efficacy and Safety Outcomes (CAPACITY) program comprised two almost identical double-blind placebo-controlled studies assessing the effects of pirfenidone on change in forced vital capacity, the primary end point, over a 72-week period. One of these studies was positive, matching in magnitude the benefit seen in two previous positive Japanese studies. The other study did not meet its primary end point but positive trends were consistent in this and a number of secondary end point indices. Safety was acceptable, comprising mainly problems of tolerability rather than toxicity. It is likely that pirfenidone will be utilised in many countries as first-line therapy and will also be included in studies of combination therapy for this attritional disease.
1747-6348
473-481
Richeldi, Luca
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
du Bois, Roland M.
5f8aef36-d70e-4902-aded-f6da129c0741
Richeldi, Luca
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
du Bois, Roland M.
5f8aef36-d70e-4902-aded-f6da129c0741

Richeldi, Luca and du Bois, Roland M. (2011) Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert Review of Respiratory Medicine, 5 (4), 473-481. (doi:10.1586/ers.11.52). (PMID:21859266)

Record type: Article

Abstract

Idiopathic pulmonary fibrosis is the most lethal form of diffuse lung fibrosis, killing approximately half of those affected within 2-3 years of diagnosis. Until recently, no therapies had been shown to have an impact on disease progression. The Clinical Studies Assessing Pirfenidone (Esbriet(®)) in IPF: Research of Efficacy and Safety Outcomes (CAPACITY) program comprised two almost identical double-blind placebo-controlled studies assessing the effects of pirfenidone on change in forced vital capacity, the primary end point, over a 72-week period. One of these studies was positive, matching in magnitude the benefit seen in two previous positive Japanese studies. The other study did not meet its primary end point but positive trends were consistent in this and a number of secondary end point indices. Safety was acceptable, comprising mainly problems of tolerability rather than toxicity. It is likely that pirfenidone will be utilised in many countries as first-line therapy and will also be included in studies of combination therapy for this attritional disease.

This record has no associated files available for download.

More information

Published date: August 2011
Organisations: Clinical & Experimental Sciences

Identifiers

Local EPrints ID: 369079
URI: http://eprints.soton.ac.uk/id/eprint/369079
ISSN: 1747-6348
PURE UUID: b2d12614-eb92-464d-aa88-e108ac974f9c

Catalogue record

Date deposited: 24 Sep 2014 11:29
Last modified: 14 Mar 2024 17:57

Export record

Altmetrics

Contributors

Author: Luca Richeldi
Author: Roland M. du Bois

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×